A few examples of the drug impact of the genetic diagnosis in this cohort include the avoidance of valproic acid in the case of MELAS syndrome due to possible toxicity of mitochondria [39], the administration of Everolimus in TSC1 Tuberous Sclerosis Complex [40], the recommendation of cannabidiol in developmental and epileptic encephalopathy SYNGAP1 [41], and the administration perampanel in NR2F1-related epilepsy [42]. Here, NR2F1 is linked to developmental and epileptic encephalopathy.